INFORMAÇÃO/FORMAÇÃO

(Circulation. 2010;121:1904-1911.)
© 2010 American Heart Association, Inc.

--------------------------------------------------------------------------------

Epidemiology and Prevention


Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke
Zeynep Binici, MD; Theodoros Intzilakis, MD; Olav Wendelboe Nielsen, MD, PhD, DMSc; Lars Køber, MD, DMSc; Ahmad Sajadieh, MD, DMSc
From the Department of Cardiology, Copenhagen University Hospital of Amager (Z.B., T.I., A.S.); Department of Cardiology, Copenhagen University Hospital of Bispebjerg (Z.B., O.W.N., A.S.); and Department of Cardiology, Rigshospitalet Copenhagen University Hospital (L.K.), Copenhagen, Denmark.

Correspondence to Zeynep Binici, MD, Department of Cardiology, Copenhagen University Hospital of Amager and Bispebjerg, Bispebjerg Bakke 23, Copenhagen 2400, Denmark. E-mail zeynep.binici@dadlnet.dk

Received May 20, 2009; accepted March 12, 2010.

Background— Prediction of stroke and atrial fibrillation in healthy individuals is challenging. We examined whether excessive supraventricular ectopic activity (ESVEA) correlates with risk of stroke, death, and atrial fibrillation in subjects without previous stroke or heart disease.

Methods and Results— The population-based cohort of the Copenhagen Holter Study, consisting of 678 healthy men and women aged between 55 and 75 years with no history of cardiovascular disease, atrial fibrillation, or stroke, was evaluated. All had fasting laboratory tests and 48-hour ambulatory ECG monitoring. ESVEA was defined as 30 supraventricular ectopic complexes (SVEC) per hour or as any episodes with runs of 20 SVEC. The primary end point was stroke or death, and the secondary end points were total mortality, stroke, and admissions for atrial fibrillation. Median follow-up was 6.3 years. Seventy subjects had SVEC 30/h, and 42 had runs of SVEC with a length of 20 SVEC. Together, 99 subjects (14.6%) had ESVEA. The risk of primary end point (death or stroke) was significantly higher in subjects with ESVEA compared with those without ESVEA after adjustment for conventional risk factors (hazard ratio=1.64; 95% confidence interval, 1.03 to 2.60; P=0.036). ESVEA was also associated with admissions for atrial fibrillation (hazard ratio=2.78; 95% confidence interval, 1.08 to 6.99; P=0.033) and stroke (hazard ratio=2.79; 95% confidence interval, 1.23 to 6.30; P=0.014). SVEC, as a continuous variable, was also associated with both the primary end point of stroke or death and admissions for atrial fibrillation.

Conclusions— ESVEA in apparently healthy subjects is associated with development of atrial fibrillation and is associated with a poor prognosis in term of death or stroke.